Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

NCT ID: NCT00003225

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-07-31
• Study Completion Date: 2001-06-30

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.

Detailed Description

OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered together in patients with metastatic colorectal cancer. II. Assess the total dose of irinotecan received per 6 week course in these patients. III. Determine the incidence of irinotecan-induced leukopenia, neutropenia, and diarrhea in these patients. V. Determine the response rate for this patient population.

OUTLINE: This is an open label study. Amifostine is administered by 10 minute IV infusions. Irinotecan is administered by IV infusions 15 minutes after completion of amifostine. Treatment is repeated every 2 weeks for 6 weeks. This 6 week course is repeated in the absence of disease progression. Treatment may be delayed up to 2 weeks after a course to allow for recovery from toxic effects. Patients are followed at the end of study and at 30 days after study.

PROJECTED ACCRUAL: There will be 25-30 patients accrued into this study.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ethyol plus Irinotecan

Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.

Group Type: EXPERIMENTAL

amifostine trihydrate

Intervention Type: DRUG

Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.

irinotecan hydrochloride

Intervention Type: DRUG

10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.

Administered every 14 days for 3 cycles

Interventions

amifostine trihydrate

Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.

Intervention Type: DRUG

irinotecan hydrochloride

10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.

Administered every 14 days for 3 cycles

Intervention Type: DRUG

Other Intervention Names

Ethyol

Eligibility Criteria

Inclusion Criteria

• 18 years of age or older
• ECOG 0-2
• Life expectancy of at least 12 weeks
• Pathologically confirmed diagnosis of metastatic colorectal cancer
• Measureable disease
• Have not received therapy for cancer within 4 weeks of enrollment on study
• Prior radiation therapy to the pelvis for treatment of colorectal cancer is allowed. Radiation therapy delivered elsewhere is allowed as long as the patient has been off treatment for at least six weeks and measurable lesions are present outside the radiation field
• Pretreatment granulocyte count of > 1500/mm3, hemoglobin > 9.0 g/dL (without transfusion), and platelet count of > 100,000/um
• Serum creatinine < 2.0 mg/dL
• Adequate hepatic function as documented by a serum bilirubin < 2.0 mg/dL regardless of whether patients have liver involvement secondary to tumor. AST must be < 3x the upper limit of normal unless the liver is involved with tumor, in which case the AST must be < 5x institutional upper limit of normal

Exclusion Criteria

• Prior therapy with Irinotecan
• Patients with any active or uncontrolled infection
• Patients with psychiatric disorders that would interfere with consent or follow-up
• Patients with a history of myocardial infarction within the previous six months, congestive heart failure, or cerebrovascular disease
• History of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years
• Presence of clinically apparent central nervous system metastases or carcinomatous meningitis
• Patients with uncontrolled diabetes mellitus
• Any other sever concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
• Patients unable to stop taking antihypertensive medication 24 hour prior to administration of Ethyol (off x 1 day)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ALZA

INDUSTRY

Sponsor Role: collaborator

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

UCLA

Principal Investigators

Diane Prager, MD

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Wilshire Oncology Medical Group, Inc.

Rancho Cucamonga, California, United States

Countries

United States

Other Identifiers

UCLA-HSPC-970304601B

Identifier Type: -

Identifier Source: secondary_id

ALZA-UCLA-HSPC-970304601B

Identifier Type: -

Identifier Source: secondary_id

NCI-G98-1390

Identifier Type: -

Identifier Source: secondary_id

CDR0000066087

Identifier Type: -

Identifier Source: org_study_id